Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The Tolerability and Safety of Psilocybin in Psychiatric and Substance-Dependence Conditions: A Systematic Review
Dana Kaminski, Justin P. Reinert
Annals of Pharmacotherapy (2023) Vol. 58, Iss. 8, pp. 811-826
Closed Access | Times Cited: 11

Showing 11 citing articles:

Are “mystical experiences” essential for antidepressant actions of ketamine and the classic psychedelics?
Kenji Hashimoto
European Archives of Psychiatry and Clinical Neuroscience (2024)
Open Access | Times Cited: 28
A retrospective study of the characteristics and toxicology of cases of lysergic acid diethylamide (LSD)‐ and psilocybin‐related death in Australia
Shane Darke, Johan Duflou, Amy Peacock, et al.
Addiction (2024) Vol. 119, Iss. 9, pp. 1564-1571
Open Access | Times Cited: 5
Single-dose psilocybin therapy for alcohol use disorder: Pharmacokinetics, feasibility, safety and efficacy in an open-label study
Mathias E. Jensen, Dea Siggaard Stenbæk, Catharina Messell, et al.
Journal of Psychopharmacology (2025)
Open Access
Exploring psilocybin’s role in mental health and palliative medicine: a path to improved well-being
Maria-Alejandra Umbacia, Marta León, Jose-Manuel Quintero, et al.
Expert Opinion on Emerging Drugs (2025)
Closed Access
Regulatory Alignment of Psilocybin Clinical Trials in Major Depressive Disorder on ClinicalTrials.gov: A Cross-Sectional Analysis
Damian Świeczkowski, Aleksander Kwaśny, Michał Pruc, et al.
Pharmacopsychiatry (2025)
Closed Access
The Influence of Stakeholder Interests on Safety Outcome Reporting in Psychedelic Research and Implications for Science Communication
Elena Koning, Marco Solmi, Elisa Brietzke
Trends in Psychiatry and Psychotherapy (2024)
Open Access | Times Cited: 2
Psilocybin mushrooms and public health in Brazil: a low-risk adverse event profile calls for evidence-based regulatory discussions
Marcel Nogueira, Solimary García-Hernández, Gleicy Sotéro Roberto, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 1
Psilocybin and other Psychedelics
Alfred P. Kaye, Benjamin Kelmendi, Merangely N. Rivera, et al.
Elsevier eBooks (2024)
Closed Access
­­­­Single-Dose Psilocybin Therapy for Alcohol Use Disorder: Pharmacokinetics, Feasibility, Safety, and Efficacy in an Open-Label Study
Mathias E. Jensen, Dea Siggaard Stenbæk, Catharina Messell, et al.
Research Square (Research Square) (2024)
Open Access
Qualitative Research on Psilocybin-Assisted Psychotherapy for the Treatment of Mental Health Disorders: A Scoping Review Protocol
J Pincombe, M.L. Williams, Sean P. Carruthers, et al.
(2024)
Open Access
Psilocybin Mushrooms and Public Health in Brazil: Insights from a Retrospective Analysis of Adverse Events and Their Implications for Regulatory Discussions
Marcel Nogueira, Solimary García-Hernández, Gleicy Sotéro Roberto, et al.
International journal of medicinal mushrooms (2024) Vol. 27, Iss. 2, pp. 13-37
Closed Access
The safety of psilocybin-assisted psychotherapy: A systematic review
Rosana Freitas, Efstathia S Gotsis, Alexander Gallo, et al.
Australian & New Zealand Journal of Psychiatry (2024)
Closed Access
Page 1

Scroll to top